Advocacy intelligence hub — real-time data for patient organizations
Merck Sharp & Dohme LLC — PHASE3
IRCCS Ospedale San Raffaele — PHASE2
IRCCS Ospedale San Raffaele
Massachusetts General Hospital — NA
Jiangsu Hansoh Pharmaceutical Co., Ltd. — PHASE1
José Claudio Casali da Rocha — PHASE2
M.D. Anderson Cancer Center
IRCCS San Raffaele
Assistance Publique - Hôpitaux de Paris — NA
Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Welireg
Merck Sharp & Dohme LLC
Welireg
(BELZUTIFAN)Orphan drugMerck Sharp & Dohme LLC
Hypoxia-inducible Factor Inhibitor [EPC]
12.1 Mechanism of Action Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role i...
Eric Jonasch, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Andrea B Apolo, M.D., MD
National Cancer Institute (NCI)
📍 BETHESDA, MD
W. Marston Linehan, M.D.
National Cancer Institute (NCI)
📍 Bethesda, Maryland
Prashant Chittiboina, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
📍 Bethesda, Maryland
Kim E. Nichols, MD
St. Jude Children's Research Hospital
📍 Memphis, Tennessee
Naris Nilubol, M.D., MD
National Cancer Institute (NCI)
📍 LONG ISLAND CITY, NY